Medical Aesthetics: A Rising Tide Lifts All Ships In A Booming Market With Room For Growth
Major players in medical aesthetics are investing in the overall growth of the market in the hope that a rising tide will lift all ships. Research shows that while millions have tried facial injectables and other non-invasive treatments, many more need one last push into the dermatologist's office.
You may also be interested in...
The only addition to AbbVie’s leadership after it closes the $63bn acquisition of Allergan will be Carrie Strom, who will lead the Allergan Aesthetics business.
New product sales doubled from $161m in the first quarter to $344m in Q3 and the R&D pipeline advancing as planned ahead of generic competition for Revlimid, which will begin to launch in 2022.
Atuzaginstat targets a bacteria associated with Alzheimer’s disease. The higher of two doses showed a 57% slowing in cognitive decline in the Phase II/III GAIN trial in mild to moderate patients with P. gingivalis infection confirmed by saliva test.